The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival

Erythropoietin Promotes the Growth of Tumors Lacking Its Receptor and Decreases Survival of Tumor-Bearing Mice by Enhancing Angiogenesis

(2015) Tatsuma Okazaki et al.   NEOPLASIA

Absence of functional EpoR expression in human tumor cell lines

(2010) S. Swift et al.   BLOOD

Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells

(2010) A. M. Sinclair et al.   BLOOD

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

(2010) J Glaspy et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

(2009) Michael A. Bookman et al.   JOURNAL OF CLINICAL ONCOLOGY

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

(2009) Julia Bohlius et al.   LANCET

Tumor Progression Associated with Erythropoiesis-Stimulating Agents

(2008) Ashley M Newland et al.   ANNALS OF PHARMACOTHERAPY

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

(2008) Charles L. Bennett   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

(2007) Gillian Thomas et al.   GYNECOLOGIC ONCOLOGY